NCT05846646 2025-10-20Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCImmuneSensor Therapeutics Inc.Phase 2 Terminated6 enrolled 7 charts
NCT04639245 2023-08-03Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerFred Hutchinson Cancer CenterPhase 1/2 Terminated1 enrolled 6 charts